ERYTECH Pharma

ERYTECH Pharma est membre de Lyonbiopôle

General information

Bâtiment Bioserra, 60 avenue Rockefeller

69008 LYON

Incorporated in: 2004/11/15

Number of employees: 213


More information

 

Main activity

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival. The company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer.


Funding

Looking for funding: Yes

Nature of funding searches: Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs http://erytech.com/pipeline.html    

Private funding obtained: June 2006 : 12 Millions Euros ; June 2010 : 5.2 Millions Euros ; April 2013 : 17.7 Millions Euros (IPO) ; October 2014 : 30 Millions Euros December 2015 : 25.4 Millions Euros December 2016 : 9.9 Millions Euros April 2017 : 70 Millions Euros November 2017 : 144 Millions US Dollars (IPO)

Public funding obtained: 2008: 600 k€ / subsidy ; 2009: 767 k€ / sub ; 215 k€ / repayable advance ; 2010: 77 k€ / sub ; 2011: Oseo:   2 M€:sub / 5  M€ : repayable advance  

Stock exchange listing: 30/04/2013: IPO in compartment C of the NYSE Euronext regulated market in Paris (17.7 Millions Euros) 10/11/2017 : IPO in US Nasdaq Global Select Market (144 Millions US Dollars)

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Immune, AutoIm & Inflam. diseases - Oncology - Metabolic Diseases


Activities
Therapeutics, Pharma or Biotech


Technologies
Cell Therapy - cell biology - Biobanking - Drug delivery device - services - Antibodies - Protein - Peptide

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte